Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
The addition of nivolumab to platinum-based chemotherapy improved pathologic complete response rates in patients with resectable stage IIIA or IIIB NSCLC. Approximately 20% of patients with non–sma…
